See past issues in our Newsletter Archives
In this issue:
Bangladesh introduces typhoid conjugate vaccine
On October 12, Bangladesh introduced typhoid conjugate vaccine (TCV) into its routine immunization program, starting with a nationwide campaign to vaccinate nearly 44 million children aged 9 months to younger than 15 years. The monthlong campaign—one of the largest TCV introduction campaigns to date—will provide vaccine at both schools and local vaccination centers to reach as many children as possible.
Bangladesh has one of the highest rates of typhoid globally, with an estimated 600,780 cases and more than 8,000 deaths attributable to the disease each year. TCVs provide strong protection against typhoid, including drug-resistant strains. Bangladesh is the third country to introduce TCV in 2025, following Burkina Faso (English | French) and Kenya’s introductions earlier this year.
Typhoid at ASTMH
Are you headed to Toronto, Canada, for the American Society of Tropical Medicine & Hygiene’s (ASTMH) annual meeting? If so, join TyVAC—and the typhoid community—for a diverse array of symposia, presentations, and posters. Come learn about data-driven strategies for typhoid prevention and response, case management of typhoid, vaccine and cost effectiveness, drug resistance, vaccine impact, boosters, typhoid intestinal perforations, systematic reviews, and more. Let’s Take on Typhoid at ASTMH!
The full lineup is here.
One typhoid case, severe complications and drug resistance
Typhoid intestinal perforation (TIP) is a severe, late complication of typhoid that disproportionately impacts children in resource-limited settings. A recent case report focuses on one patient in Niger with TIP and a damaged gallbladder, caused by typhoid. Drug resistance is making typhoid harder to treat and serious complications—like TIP—more common.
In addition to TIP and gallbladder damage, this patient had a drug-resistant type of Echerichiai coli (E. coli) bloodstream infection called extended-spectrum beta-lactamase (ESBL)-producing E. coli, which complicates treatment. This is the first reported case of ESBL E. coli occurring with TIP and gallbladder damage in a pediatric patient. Luckily, a single dose of TCV is safe and effective for children older than 6 months of age and provides protection for at least 4 years. Kudos to Niger for their planned TCV introduction later this year!
2026 International Conference on Typhoid and Other Invasive Salmonelloses
Planning is underway for the 2026 International Conference on Typhoid and Other Invasive Salmonelloses, taking place March 24-26, 2026, in Phnom Penh, Cambodia. Centered on the theme “Innovation and Equity: Shaping the Future of Typhoid and Other Invasive Salmonelloses,” the conference will bring together global experts, researchers, and policymakers to explore cutting-edge science and equitable solutions for typhoid prevention and control.
Registration for the conference is now open. Symposia and workshop submissions are also open through November 14, 2025, Cambodia time. The Coalition against Typhoid is pleased to offer a limited number of travel awards to support individuals working in the typhoid, paratyphoid, and invasive nontyphoidal Salmonella field who would otherwise be unable to attend. Priority will be given to researchers from low- and middle-income countries, with selection based on abstract quality and demonstrated commitment to the field. Applications for travel awards will be accepted until December 12, 2025.
Outbreak report
Ghana: The Ghana Health Service, in collaboration with the Oti Regional Coordinating Council, are coordinating efforts to respond to a reported surge in suspected typhoid cases in the Oti Region in eastern Ghana. The affected districts include Biakoye, Krachi East, Krachi West, and Krachi Nchumuru.
